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Abstract
Background: Prospective data on the associations of adiponectin with in-vivo measurements of degree, phenotype and 
vulnerability of coronary atherosclerosis are currently lacking.
Objective: To investigate the association of plasma adiponectin with virtual histology intravascular ultrasound (VH-IVUS)-
derived measures of atherosclerosis and with major adverse cardiac events (MACE) in patients with established coronary 
artery disease.
Methods: In 2008-2011, VH-IVUS of a non-culprit non-stenotic coronary segment was performed in 581 patients undergoing 
coronary angiography for acute coronary syndrome (ACS, n = 318) or stable angina pectoris (SAP, n = 263) from the 
atherosclerosis-intravascular ultrasound (ATHEROREMO-IVUS) study. Blood was sampled prior to coronary angiography. 
Coronary plaque burden, tissue composition, high-risk lesions, including VH-IVUS-derived thin-cap fibroatheroma (TCFA), 
were assessed. All-cause mortality, ACS, unplanned coronary revascularization were registered during a 1-year-follow-up. 
All statistical tests were two-tailed and p-values < 0.05 were considered statistically significant.
Results: In the full cohort, adiponectin levels were not associated with plaque burden, nor with the various VH-tissue 
types. In SAP patients, adiponectin levels (median[IQR]: 2.9(1.9-3.9) μg/mL) were positively associated with VH-IVUS 
derived TCFA lesions, (OR[95%CI]: 1.78[1.06-3.00], p = 0.030), and inversely associated with lesions with minimal 
luminal area (MLA) ≤ 4.0 mm2 (OR[95%CI]: 0.55[0.32-0.92], p = 0.025). In ACS patients, adiponectin levels (median[IQR]: 
2.9 [1.8‑4.1] μg/mL)were not associated with plaque burden, nor with tissue components. Positive association of adiponectin 
with death was present in the full cohort (HR[95%CI]: 2.52[1.02–6.23], p = 0.045) and (borderline) in SAP patients 
(HR[95%CI]: 8.48[0.92–78.0], p = 0.058). In ACS patients, this association lost statistical significance after multivariable 
adjustment (HR[95%CI]: 1.87[0.67-5.19], p = 0.23).
Conclusion: In the full cohort, adiponectin levels were associated with death but not with VH-IVUS atherosclerosis 
measures. In SAP patients, adiponectin levels were associated with VH-IVUS-derived TCFA lesions. Altogether, substantial 
role for adiponectin in plaque vulnerability remains unconfirmed. (Arq Bras Cardiol. 2018; 111(3):345‑353)
Keywords: Adiponectin; Atherosclerosis; Plaque, Atherosclerotic; Ultrasonography, Interventional; Coronary Artery 
Disease / complications.
Introduction
Coronary plaque rupture has been described as the 
main mechanism through which mildly stenotic coronary 
atherosclerosis can lead to acute coronary thrombosis and 
myocardial infarction.1 High-risk plaques that are vulnerable 
to such rupture demonstrate distinct morphological 
characteristics.2 They can be differentiated from lesions 
responsible for stable coronary artery disease (CAD) by their 
large necrotic cores, thin inflamed fibrous caps, and positive 
remodeling.2 Because plaque vulnerability is associated 
with inflammation, neovascularization, and necrotic core 
formation, circulating mediators of these processes may 
aid in detection of high-risk patients and therefore warrant 
investigation.3 One important inflammatory mediator of CAD 
is adiponectin. Adiponectin is a protein mainly produced in 
white adipose tissue, involved in several antioxidant, anti-
inflammatory, and anti-atherosclerotic processes.4-6 Several 
studies have demonstrated associations of adiponectin 
with clinical adverse coronary events.7-10 Yet, prospective 
data on the associations of adiponectin with in-vivo 
measurements of degree, phenotype and vulnerability of 
coronary atherosclerosis are currently lacking. To further 
elucidate the pathophysiology of adiponectin in patients 
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with established CAD, we investigated the association of 
adiponectin with virtual histology intravascular ultrasound 
(VH-IVUS)-derived measures of degree and composition of 
coronary atherosclerosis, and with major adverse cardiac 
events (MACE), in patients undergoing coronary angiography.
Methods
The design of The European Collaborative Project on 
Inflammation and Vascular Wall Remodeling in Atherosclerosis 
– Intravascular Ultrasound (ATHEROREMO-IVUS) study has 
been described in detail elsewhere.11,12 In brief, 581 patients 
who underwent diagnostic coronary angiography or 
percutaneous coronary intervention (PCI) for acute coronary 
syndrome (ACS, n=318) or stable angina pectoris (SAP, 
n = 263) have been included between 2008 and 2011 
in the Erasmus University Medical Center (Erasmus MC), 
Rotterdam, the Netherlands. The ATHEROREMO-IVUS study 
was approved by the medical ethics committee of Erasmus 
MC. The study was performed in accordance with the criteria 
described in the declaration of Helsinki. Written informed 
consent was obtained from all included patients. This study 
is registered in ClinicalTrials.gov, number NCT01789411.
Blood samples for biomarker measurements were drawn 
from the arterial sheath prior to coronary angiography and 
were available in 570 patients for the current study. The blood 
samples were stored at the clinical laboratory of Erasmus 
MC at a temperature of -80°C within 2 hours after blood 
collection. C-reactive protein (CRP) was measured in serum 
samples using an immunoturbidimetric high sensitivity assay 
(Roche Diagnostics Ltd., Rotkreuz, Switzerland) on the Roche 
Cobas 8000 modular analyzer platform. These analyses 
were performed in the clinical laboratory of Erasmus MC. 
Frozen EDTA plasma samples were transported under controlled 
conditions (at a temperature of -80°C) to Myriad RBM, Austin, 
Texas, USA, where adiponectin was measured using a validated 
multiplex assay (Custom Human Map, Myriad RBM).
Following the standard coronary angiography or PCI 
procedure, intravascular ultrasound (IVUS) imaging took 
place in a target segment of a non-culprit coronary artery 
which was required to be at least 40 mm in length and 
without significant luminal narrowing (< 50% stenosis) as 
assessed by on-line angiography. Selection of the non-culprit 
vessel was predefined in the study protocol. The order of 
preference for selection of the non-culprit vessel was: (1) left 
anterior descending (LAD) artery; (2) right coronary artery 
(RCA); (3) left circumflex (LCX) artery. All IVUS data were 
acquired with the Volcano s5/s5i Imaging System (Volcano 
Corp., San Diego, California) using a Volcano Eagle Eye Gold 
IVUS catheter (20 MHz). An automatic pullback system was 
used with a standard pullback speed of 0.5 mm per second. 
The IVUS images were analyzed offline by an independent 
core laboratory (Cardialysis BV, Rotterdam, the Netherlands) 
blinded for clinical and biomarker data. The IVUS gray-scale 
and IVUS radiofrequency analyses, also known as VH-IVUS, 
were performed using pcVH 2.1 and qVH (Volcano Corp., San 
Diego, California) software. The external elastic membrane 
and luminal borders were contoured for each frame (median 
inter-slice distance, 0.40 mm). Extent and phenotype of the 
atherosclerotic plaque were assessed. Plaque volume was 
defined as the total volume of the external elastic membrane 
occupied by atheroma.13 Plaque burden was defined as 
plaque and media cross-sectional area divided by external 
elastic membrane cross-sectional area and is presented as a 
percentage. The composition of the atherosclerotic plaque 
was characterized into four different tissue types: fibrous, 
fibrofatty, dense calcium and necrotic core.14 A coronary lesion 
was defined as a segment with a plaque burden of more than 
40% in at least three consecutive frames. The following types 
of VH-IVUS high-risk lesions were identified: 
(1) thin-cap fibroatheroma (TCFA) lesions: lesions with 
presence of >10% confluent necrotic core in direct 
contact with the lumen;15,16 
(2) TCFA lesions with a plaque burden of at least 70%; 
(3) lesions with a plaque burden of at least 70%; 
(4)	lesions	with	a	minimal	luminal	area	(MLA)	of	≤4.0	mm2.11
Follow-up started at inclusion and lasted 1 year. 
Post-discharge survival status was obtained from municipal civil 
registries. Post-discharge rehospitalizations were prospectively 
assessed during follow-up. Questionnaires focusing on 
the occurrence of MACE were sent to all living patients. 
Subsequently, hospital discharge letters were obtained, 
and treating physicians and institutions were contacted for 
additional information whenever necessary. ACS was defined 
as the clinical diagnosis of ST-segment elevation myocardial 
infarction (STEMI), non-STEMI or unstable angina pectoris in 
accordance with the guidelines of the European Society of 
Cardiology.17-19 Unplanned coronary revascularization was 
defined as unplanned repeat PCI or coronary artery bypass 
grafting (CABG). The primary clinical endpoint was MACE, 
defined as all-cause mortality, ACS or unplanned coronary 
revascularization. Secondary endpoints included acute MACE 
(defined as the composite of all-cause mortality or ACS) and 
all-cause mortality. The endpoints were adjudicated by a 
clinical event committee blinded for biomarker and IVUS data.
Statistical analysis
The distributions of continuous variables, including 
adiponectin levels and IVUS parameters, were evaluated 
for normality by visual examination of the histogram. 
Normally distributed variables are presented as mean ± 
standard deviation (SD), while non-normally distributed 
variables are presented as median and interquartile range (IQR). 
Adiponectin concentration was not normally distributed and 
was therefore ln-transformed for further analysis. Categorical 
variables are presented in percentages. We examined 
associations of adiponectin concentrations with plaque 
burden, plaque volume, necrotic core fraction, dense calcium 
fraction, fibro-fatty fraction, and fibrous tissue fraction in the 
imaged coronary segment by linear regression, with continuous 
ln-transformed adiponectin concentration as the independent 
variable. Furthermore, we examined the relation between 
adiponectin concentrations and the presence of high-risk 
lesions using logistic regression analyses, with continuous 
ln-transformed adiponectin concentration as the independent 
variable. Cox proportional hazards regression analyses were 
performed to evaluate the relationship between adiponectin 
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concentration and MACE. Clinical variables age, gender, 
diabetes mellitus, hypertension, and indication for coronary 
angiography were considered as potential confounders and 
were entered into the full model. These covariates were a priori 
chosen based on existing literature, and taking into account the 
number of events available. CRP was also entered into the full 
model, as it is the most widely investigated inflammatory marker 
in CAD, and has been shown to be (inversely) associated with 
plasma adiponectin levels.10 When analyzing the association of 
adiponectin with the secondary, composite endpoint of death 
and ACS, and death alone, we only adjusted for age and gender 
because of the limited number of endpoints.
First, statistical analyses were performed in the full cohort. 
Then, we included interaction terms (adiponectin multiplied 
by indication for angiography) into the models to investigate 
possible effect modification by indication. Subsequently, we 
repeated the analyses separately in patients with SAP and 
patients with ACS. All data were analyzed with SPSS software 
(SPSS 20.0, IBM corp., Armonk, New York). All statistical 
tests were two-tailed and p-values < 0.05 were considered 
statistically significant.
Results
Mean age of the patients was 61.5±11.4 years, 75.4% 
were men, 17.4% had diabetes mellitus, and median 
adiponectin concentration was 2.8 (1.9-4.0) μg/mL (Table 1). 
Coronary angiography or PCI was performed for ACS in 309 
(54.2%) patients and for SAP in the remaining 261 (45.8%). 
Median adiponectin concentration was 2.9 (1.8-4.1) μg/mL in 
ACS patients and 2.9 (1.9-3.9) μg/mL in SAP patients. A total 
of 239 (41.9%) patients had at least 1 VH-IVUS-derived TCFA, 
including 69 (12.1%) patients with at least 1 VH-IVUS-derived 
TCFA	with	a	plaque	burden	≥	70%.
In the full cohort, adiponectin levels were not associated 
with composition or burden of atherosclerosis on multivariable 
analysis (Tables 2 and 3). Adiponectin levels were not 
associated with MACE after adjustment for age, gender 
and indication for angiography (Table 4). After further 
multivariable adjustment, effect estimates remained 
non-significant (data not shown). Adiponectin levels tended 
to be univariably associated with acute MACE, (median 
[IQR] 1.16[0.82-1.62] μg/mL, vs. 1.02[0.64-1.38] μg/mL; 
HR [95%CI]: 1.77[0.96–3.23], p = 0.069), but after further 
adjustment this tendency disappeared. Adiponectin levels 
were independently associated with occurrence of death 
(median[IQR]1.48(1.03-1.79) μg/mL vs. 1.02(0.64-1.36) μg/mL, 
HR[95%CI]: 2.52[1.02–6.23], p = 0.045).
Signs of interactions between adiponectin and indication 
for angiography were present for associations with TCFA (p for 
interaction 0.050 (univariable) and 0.029 (multivariable)), with 
lesions	with	MLA	≤	4.0	(p	for	interaction	0.058	(univariable)	
and 0.10 (multivariable)), and with fibrofatty tissue fraction 
(p for interaction 0.042 (univariable) and 0.082 (multivariable)). 
The remaining interaction terms were not significant 
(data not shown).
In patients with SAP, adiponectin levels were associated with 
the presence of VH-IVUS-derived TCFA lesions (median[IQR] 
1.16[0.72-1.48] μg/mL vs. 0.95[0.62-1.30] μg/mL; OR[95%CI] 
per 1 unit increase in ln-transformed-adiponectin: 1.78[1.06-
3.00], p = 0.030) (Table 3). Furthermore, adiponectin 
levels were inversely associated with presence of lesions 
with	MLA	≤	4.0	mm2 (median[IQR] 0.95[0.49-1.30] μg/mL 
vs. 1.06[0.69-1.41] μg/mL; OR [95%CI]: 0.55[0.32-0.93], 
p = 0.025) (Table 3). Finally, adiponectin levels were 
associated with death (median[IQR] 1.62[1.32-1.84] μg/mL 
vs. 1.02[0.64-1.36] μg/mL; HR [95%CI]: 8.15[1.49-44.68]). 
After adjustment for age and gender, the HR remained 
similar in magnitude, although statistical significance was lost 
(HR [95%CI: 8.48[0.92 – 78.03], p = 0.058).
In patients with ACS, no associations were present between 
adiponectin and composition or burden of atherosclerosis. 
Although no associations were present with MACE or acute 
MACE, a tendency toward a univariable association with 
death was present (median[IQR] 1.39[0.90-1.86] μg/mL 
vs. 1.01[0.60-1.38] μg/mL; HR [95%CI]: 2.44[0.98-6.06], 
p = 0.055). After adjustment for age and gender, statistical 
significance was lost (HR [95%CI]: 1.87[0.67-5.19], p = 0.23).
Given the positive associations we found between 
adiponectin and death, we performed a post-hoc analysis to 
explore whether a synergistic effect of adiponectin and TCFA 
was present on death. For this purpose, we entered interaction 
terms into the models that consisted of adiponectin multiplied 
by presence of TCFA lesions. However, no effect modification 
could be demonstrated (interaction terms were not significant).
Discussion
To our best knowledge, this is the largest study that 
correlates circulating adiponectin with in-vivo measurements 
of coronary atherosclerosis using VH-IVUS in patients with 
known coronary disease. We found that in the full cohort, 
adiponectin levels were associated with death during 1-year 
follow-up, but not with VH-IVUS measures of atherosclerosis. 
In patients with SAP, adiponectin levels were positively 
associated with presence of VH-IVUS-derived TCFA lesions 
and were inversely associated with presence of lesions 
with	MLA	≤	 4.0	mm2; while the association with death 
was borderline significant. In ACS patients we only found a 
tendency toward an association with death during follow-up.
Fundamental experiments, animal models and human 
studies on vascular function in subjects free of symptomatic 
cardiovascular disease have all demonstrated associations 
of adiponectin with vasoprotective mechanisms, including 
insulin-sensitizing characteristics and anti-oxidative 
and anti-inflammatory properties.4-6,8,10 In line with 
this, higher levels of adiponectin have been linked to 
decreased prevalence of CAD in healthy individuals 
and have demonstrated an inverse association with risk 
of myocardial infarction.20,21 However, in patients with 
manifested CAD, adiponectin seems to play a different 
role. When elevated in patients with symptomatic CAD, 
this adipocytokine becomes associated with an increased 
risk of cardiovascular events; a phenomenon that has been 
described under the term “reverse epidemiology”.22-25 
To explain these conflicting findings, it has been proposed 
that increased adiponectin levels reflect a compensatory and 
vasculoprotective mechanism.25 Specifically, in conditions 
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Table 1 – Baseline characteristics
Total (n = 570) ACS patients (n = 309) SAP patients (n = 261)
Patient characteristics
Age, years (mean±SD) 61.5 ± 11.4 59.7 ± 11.9 63.6 ± 10.3
Men, n (%) 430 (75.4) 227 (73.5) 203 (77.8)
Diabetes Mellitus, n (%) 99 (17.4) 40 (12.9) 59 (22.6)
Hypertension, n (%) 295 (51.8) 134 (43.4) 161 (61.7)
Hypercholesterolemia, n (%) 317 (55.6) 137 (44.3) 180 (69.0)
Smoking, n (%) 164 (28.8) 115 (37.2) 49 (18.8)
Positive family history, n (%) 293 (51.5) 140 (45.3) 153 (58.6)
Previous MI, n (%) 184 (32.3) 80 (25.9) 104 (58.6)
Previous PCI, n (%) 185 (32.5) 57 (18.4) 128 (49.0)
Previous CABG, n (%) 18 (3.2) 7 (2.3) 11 (4.2)
Previous stroke, n (%) 23 (4.0) 10 (3.2) 13 (5.0)
Peripheral artery disease, n (%) 36 (6.3) 12 (3.9) 24 (9.2)
History of renal insufficiency (%) 32 (5.6) 13 (4.2) 19 (7.3)
History of heart failure, n (%) 19 (3.3) 6 (1.9) 13 (5.0)
Procedural characteristics
Indication for coronary angiography 
Acute coronary syndrome, n (%) 309 (54.2) 309 (100) 0 (0)
Myocardial infarction, n (%) 159 (27.9) 159 (51.5) 0 (0)
Unstable angina pectoris, n (%) 150 (26.3) 150 (48.5) 0 (0)
Stable angina pectoris, n (%) 261 (45.8) 0 (0) 261 (100)
Coronary artery disease
No significant stenosis, n (%) 42 (7.4) 18 (5.8) 24 (9.2)
1-vessel disease, n (%) 301 (52.8) 168 (54.4) 133 (51.0)
2-vessel disease, n (%) 166 (29.1) 88 (28.5) 78 (29.9)
3-vessel disease, n (%) 61 (10.7) 35 (11.3) 26 (10.0)
PCI performed, n (%) 501 (87.9) 287 (92.9) 214 (82.0)
IVUS characteristics
Segment length (mm), median (IQR) 44.1 (33.7-55.4) 43.9 [32.9-54.1] 44.8 [34.2-57.2]
Plaque burden (%), median (IQR) 39.2 (30.0-46.4) 37.2 [28.0-45.5] 40.2 [31.8-47.8]
Presence lesion with MLA ≤ 4.0mm2 176 (30.9) 88 (28.7) 88 (33.7)
Presence of VH-TCFA, n (%) 239 (41.9) 140 (45.5) 99 (37.9)
Presence of VH-TCFA with PB ≥ 70%, n (%) 69 (12.1) 32 (10.4) 37 (14.2)
Serum biomarker concentrations
C-reactive protein (mg/L), median [IQR] 2.1 [0.8-5.3] 2.8 [1.1-7.0] 1.5[0.6-3.1]
Adiponectin (μg/mL) median [IQR] 2.8 [1.9-4.0] 2.9 [1.8-4.1] 2.9 [1.9-3.9]
ACS: acute coronary syndrome; SAP: stable angina pectoris; SD: standard deviation; MI: myocardial infarction; PCI: percutaneous coronary intervention; 
CABG: coronary artery bypass grafting; IVUS: intravascular ultrasound; IQR: interquartile range; MLA: minimal luminal area; VH-TCFA: virtual histology thin-cap 
fibroatheroma; PB: plaque burden.
characterized by a marked systemic pro-inflammatory state 
and endothelial dysfunction, adiponectin levels increase 
as an attempt to counter-regulate or compensate for this 
systemic inflammation. Consequently, the protective effects 
of adiponectin are superseded by the underlying disease.25
In a cohort of 981 patients with stable ischemic heart disease, 
with average follow-up of 7.1 years, an association was found 
between higher adiponectin and adverse cardiovascular events 
(death, heart failure), but after adjustment for cardiac disease 
severity, the association was no longer statically significant.24 
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Table 2 – Association of adiponectin plasma levels with segment intravascular ultrasound characteristics in the total study cohort, acute 
coronary syndrome and stable angina patients
IVUS characteristics
Unadjusted Model
p
Multivariable model*
p
Beta ‡ (95% CI) Beta ‡ (95% CI) 
All patients (n = 570) Segment plaque Burden -0.40 (-2.04 – 1.23) 0.62 -0.95 (-2.74 – 0.85) 0.30
Dense calcium fraction % 1.35 (0.27 – 2.44) 0.001 0.36 (-0.86 – 1.58) 0.56
Necrotic core fraction % 0.43 (-0.71 – 1.58) 0.46 0.39 (-0.92 – 1.70) 0.56
Fibrofatty tissue fraction % -0.62 (-1.51 – 0.27) 0.17 -0.46 (-1.46 – 0.55) 0.37
Fibrous tissue fraction % -1.17 (-2.81 – 0.48) 0.17 -0.29 (-2.16 – 1.58) 0.76
ACS patients (n = 309) Segment plaque Burden 0.03 (-2.27 – 2.33) 0.98 -0.89 (-3.42 – 1.63) 0.49
Dense calcium fraction % 2.53 (0.92 – 3.78) 0.001 1.10 (-0.50 – 2.70) 0.18
Necrotic core fraction % 0.56 (-1.12 – 2.24) 0.51 0.23 (-1.69 – 2.16) 0.81
Fibrofatty tissue fraction % -1.47 (-2.78 – -0.15) 0.029 -0.99 (-2.49 – 0.50) 0.19
Fibrous tissue fraction % -1.45 (-3.78 – 0.89) 0.22 -0.35 (-3.00 – 2.30) 0.80
SAP patients (n = 261) Segment plaque Burden -0.71 (-3.00 – 1.58) 0.54 -0.87 (-3.46 – 1.73) 0.51
Dense calcium fraction % 0.39 (-1.25 – 2.01) 0.64 -0.41 (-2.28 – 1.47) 0.67
Necrotic core fraction % 0.24 (-1.29 – 1.77) 0.76 0.57 (-1.20 – 2.35) 0.52
Fibrofatty tissue fraction % 0.38 (-0.80 – 1.57) 0.52 0.01 (-1.32 – 1.34) 0.99
Fibrous tissue fraction % -1.01 (-3.31 – 1.30) 0.39 -0.17 (-2.82 –2.48) 0.90
*Adjusted for age, gender, diabetes, hypertension, and C-reactive protein (CRP). Additionally adjusted for indication for coronary angiography in the total cohort. 
†Logarithmically transformed. ‡ Beta per unit increase in ln-transformed adiponectin concentration. IVUS: intravascular ultrasound; CI: confidence interval of 95%; 
ACS: acute coronary syndrome; SAP: stable angina pectoris; CRP: C-reactive protein.
Table 3 – Association of adiponectin with presence of virtual histology intravascular ultrasound-derived high-risk lesions in the total cohort, 
acute coronary syndrome and stable angina patients
Unadjusted Model
p
Multivariable model*
p
OR† (95% CI) OR† (95% CI)
Total cohort (n = 570)
TCFA 1.11 (0.84 – 1.49) 0.44 1.23 (0.88 – 1.71) 0.23
TCFA PB ≥70% 0.88 (0.57 – 1.37) 0.55 0.81 (0.50 – 1.33) 0.42
Lesion with MLA ≤ 4.0 mm2 0.84 (0.62 – 1.14) 0.25 0.70 (0.49 – 1.00) 0.052
Lesion with PB ≥70% 1.02 (0.72 – 1.44) 0.93 0.93 (0.63– 1.39) 0.73
ACS patients (n = 309)
TCFA 0.85 (0.58 – 1.26) 0.42 0.90 (0.58 – 1.42) 0.66
TCFA PB ≥70% 0.90 (0.57 – 1.42) 0.66 0.77 (0.37 – 1.58) 0.48
Lesion with MLA ≤ 4.0 mm2 1.13 (0.74 – 1.74) 0.57 0.87 (0.53 – 1.44) 0.59
Lesion with PB ≥70% 1.25 (0.76 – 2.07) 0.38 1.08 (0.60 – 1.94) 0.80
SAP patients (n = 261)
TCFA 1.54 (0.99 – 2.38) 0.057 1.78 (1.06 – 3.00) 0.030
TCFA PB ≥70% 0.86 (0.48 – 1.52) 0.60 0.87 (0.45 – 1.69) 0.68
Lesion with MLA ≤ 4.0 mm2 0.62 (0.40 – 0.97) 0.035 0.55 (0.32 – 0.93) 0.025
Lesion with PB ≥70% 0.86 (0.54 – 1.39) 0.54 0.85 (0.49 – 1.47) 0.56
*Adjusted for age, gender, diabetes, hypertension, and C-reactive protein (CRP). Additionally adjusted for indication for coronary angiography in the total cohort. 
OR: odds ratio; CI: confidence interval of 95%; TCFA: thin-cap fibroatheroma; PB: plaque burden; MLA: minimal luminal area; ACS: acute coronary syndrome; 
SAP: stable angina pectoris. †Odds ratio per unit increase in ln-transformed biomarker concentration
Another cohort with median follow-up of 2.5 years found 
that higher adiponectin levels were associated with future 
cardiovascular death or nonfatal myocardial infarction in SAP 
patients (n = 1130), but found no association in ACS patients 
(n = 760).22 Our results, demonstrating an association of 
adiponectin with death in SAP patients, comply with these 
findings. The lack of statistical significance for this association in 
ACS patients in our study may, in part, have been caused by a 
limited number of clinical events. Moreover, pathophysiological 
differences may possibly have contributed to the difference 
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Table 4 – Association of adiponectin with major adverse cardiac events, secondary endpoints and death
Univariable
p
Adjusted for age and gender†
p
HR* (95% CI) HR* (95% CI)
Total (n = 570)
MACE (n = 56) 1.28 (0.81 – 2.02) 0.29 1.19 (0.71 – 1.99) 0.52
Acute MACE (n = 32) 1.77 (0.96 – 3.23) 0.069 1.36 (0.68 – 2.72) 0.38
Death (n = 19) 3.36 (1.49 – 7.59) 0.004 2.52 (1.02 – 6.23) 0.045
ACS (n = 309)
MACE (n = 26) 1.29 (0.66 – 2.50) 0.46 1.02 (0.48 – 2.19) 0.95
Acute MACE (n = 20) 1.75 (0.81 – 3.72) 0.14 1.40 (0.59 – 3.29) 0.44
Death (n = 14) 2.44 (0.98 – 6.06) 0.055 1.87 (0.67 – 5.19) 0.23
SAP (n = 261)
MACE (n = 30) 1.30 (0.69 – 2.46) 0.42 1.43 (0.69 – 2.98) 0.34
Acute MACE (n = 12) 1.75 (0.61 – 4.94) 0.29 1.33 (0.41 – 4.28) 0.64
Death (n = 5) 8.15 (1.49 – 44.68) 0.016 8.48 (0.92 – 78.03) 0.058
HR: hazard ratio; CI: confidence interval of 95%; MACE: major adverse cardiac events; ACS: acute coronary syndrome; SAP: stable angina pectoris; 
Acute MACE: composite of death or acute coronary syndrome (secondary endpoints). †Additionally adjusted for indication for coronary angiography in the total 
cohort. * Hazard ratio per unit increase in ln-transformed biomarker concentration
we found between SAP and ACS. While in SAP patients, 
atherosclerosis appears to be a slowly progressing disorder, in 
ACS patients, coronary plaque rupture may be present, and 
the latter is accompanied by the production of tissue factor and 
other homeostatic factors that increase the risk of thrombosis.3 
Plasma adiponectin levels have been inversely correlated with 
markers of platelet activation.26,27 This might have possibly 
influenced the association between adiponectin and clinical 
outcome in these patients.
Adipose tissue produces both pro- and anti-inflammatory 
adipocytokines,10 and adiponectin has shown in vitro and in 
vivo anti-inflammatory effects.28 However, little is known about 
the clinical significance of adiponectin for coronary plaque 
stability in vivo. Only a few studies have been performed 
on this topic, all of which at the University of Kobe, Japan. 
Sample size of these studies was modest. In a randomized trial 
of 54 patients with type 2 diabetes and stable angina, treated 
with pioglitazone, adiponectin was found to be associated 
with a reduction of necrotic core components as assessed by 
VH-IVUS.29 A case control study of 63 ACS and 43 non-ACS 
patients showed that serum adiponectin was inversely 
associated with necrotic core evaluated by VH-IVUS in both 
culprit and non-culprit lesions in patients with ACS, but not 
in those with stable angina.30 In 50 men with stable CAD, low 
plasma adiponectin was associated with presence of TCFA.31 
Altogether, these studies point toward an inverse association 
of adiponectin with plaque vulnerability. In contrast, in our 
study, we found a positive association of adiponectin with 
VH-IVUS TCFA in SAP patients. This finding is in line with 
the association of adiponectin with death, as well as the 
association of VH-IVUS TCFA with adverse outcome which 
we demonstrated earlier.12 However, the exact mechanism 
behind the positive association between adiponectin and 
VH-IVUS-derived TCFA lesions warrants further investigation. 
With regard to the discrepancy between our study and the 
Japanese ones, differences in study population and sample size 
could have played a part. Ethnic differences in adiponectin 
levels are of particular interest in this context. The Mediators 
of Atherosclerosis in South Asians Living in America (MASALA) 
study and the Multi-Ethnic Study of Atherosclerosis (MESA) 
have shown that adiponectin levels are lowest in persons from 
South Asian or Chinese descent compared to other ethnic 
groups.32 Moreover, polymorphisms in the adiponectin gene 
have been found to be associated with adiponectin levels.33 
Some of these polymorphisms have also shown associations 
with insulin resistance, metabolic syndrome and the onset 
of CAD.32-34 Finally, while we found a positive association of 
adiponectin with VH-IVUS TCFA, we could not demonstrate 
such an association with necrotic core fraction. This seeming 
discrepancy may be explained by the fact that these measures 
reflect somewhat different aspects of atherosclerosis. 
Size of necrotic core fraction alone may not be able to fully 
capture the properties of rupture-prone plaques; the definition 
of VH-IVUS TCFA on its part incorporates additional plaque 
properties, such as confluence of the necrotic core and direct 
contact of the necrotic core with the lumen.
Some limitations of this study need to be acknowledged. 
The spatial resolution of VH-IVUS (200 μm) is insufficient to 
exactly replicate histopathological definitions of a thin fibrous 
cap (<65 μm).13 Therefore, VH-IVUS tends to over-estimate 
the number of TCFA lesions. Nevertheless, the presence 
of VH-IVUS-detected TCFA lesions carries prognostic 
information12 and is therefore clinically relevant. Furthermore, 
VH-IVUS imaging was performed in a prespecified single 
target segment of a single non-culprit coronary artery.35 
This approach was chosen because previous studies have 
demonstrated that such segments reflect larger coronary 
disease burden and are associated with subsequent cardiac 
events.12,36 Finally, adiponectin was associated with mortality, 
but the number of deaths in our dataset was small.
Conclusion
In conclusion, in the full cohort, adiponectin levels were 
associated with death but not with VH-IVUS measures of 
atherosclerosis. In SAP patients, adiponectin levels were 
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associated with VH-IVUS derived TCFA lesions, while the 
association with death was borderline significant. Altogether, a 
substantial role for adiponectin in plaque vulnerability remains 
unconfirmed and warrants investigation by other, large studies.
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